DEMANT

Overview

Demant is a hearing healthcare company whose businesses span Hearing Care, Hearing Aids and Diagnostics. It develops and sells hearing aids and diagnostic equipment, and provides hearing-care services through a global clinic network. The company describes its purpose as creating life-changing differences through hearing health and helping people enjoy life.[1][2]

Demant reports operations in more than 30 countries and sales in more than 130; its Hearing Care business operates over 4,500 clinics in more than 25 countries.[1][3] It was founded in 1904.[4] For scale, revenue was DKK 22,971 million in FY2025 and DKK 12,913 million in the first half of 2026; reported headcount at 30 June 2026 was 26,616.[5]+2 [2]+6

Products & services

Demant’s hearing-aid portfolio includes Oticon, Bernafon and Philips. Named Oticon products include **Zeal**, a discreet rechargeable in-ear hearing aid with connectivity and second-generation AI sound processing; **Reveal**, a rechargeable premium model with Dual AI sound processing; **Verit**, designed for users preferring disposable batteries; and **Play SI**, a pediatric product family. The company describes its hearing-aid portfolio as AI-driven.[8]+3

In Diagnostics, Demant’s Interacoustics products include the **Equinox Evo**, a clinical PC-based audiometer for traditional speech and tone audiometry as well as advanced testing such as Audible Contrast Threshold (ACT), and **LUNA**, a portable Type 4 screening audiometer. Demant’s hearing-care services include hearing assessment and support through hearing-aid fitting.[12]+4

For context on business-area mix, H1 2026 external revenue was DKK 5,153 million for Hearing Aids, DKK 6,538 million for Hearing Care and DKK 1,222 million for Diagnostics, out of group revenue of DKK 12,913 million—approximately 39.9%, 50.6% and 9.5%, respectively, calculated from the reported figures. These are business-area shares, not product-level percentages. Demant completed the sale of Oticon Medical in March 2026, concluding its divestment of the Hearing Implants business.[6]+2 [8]+11

Geographic presence

Demant’s geographic footprint spans Europe, North America, Asia, the Pacific region and other markets. In H1 2026, revenue was DKK 6,270 million in Europe (about 48.6% of total), DKK 4,692 million in North America (36.3%), DKK 1,033 million in Asia (8.0%), DKK 562 million in the Pacific region (4.4%) and DKK 356 million in the rest of the world (2.8%). The company reported regional rather than country-level revenue.[18]

At year-end 2025, Demant owned and operated more than 4,500 hearing-care clinics in more than 25 countries.[3] Its headquarters are in Smørum, Denmark.[19] The FY 2025 annual report listed non-current assets of DKK 17,331 million in Europe, DKK 7,367 million in North America, DKK 1,805 million in Asia, DKK 798 million in the Pacific region and DKK 135 million in the rest of the world; these are asset values, not revenue.[20] Demant reported 26,704 employees at year-end 2025, but the cited disclosure does not break employment down geographically.[21] [18]+5

Business segments

Demant’s FY2025 business-area breakdown comprises Hearing Aids, Hearing Care and Diagnostics. By reported revenue mix, Hearing Aids (external revenue) contributed approximately 43% (about DKK 9.9bn), Hearing Care 47% (about DKK 10.8bn), and Diagnostics 10% (about DKK 2.3bn), based on group revenue of DKK 22,971m. The percentages are rounded, so the implied amounts are approximate.[22] Hearing Aids covers the company’s hearing-aid products and brands, including Oticon, Bernafon and Philips.[8][23] Hearing Care comprises retail hearing-care operations and clinics, while Diagnostics focuses on audiological and hearing-instrument fitting equipment, as well as balance-related products and associated services.[24][25]

These are the continuing business areas in Demant’s operating model. The company also discloses revenue geographically, but those regional disclosures are not additional business areas.[26][27] Communications (EPOS) and Hearing Implants (Oticon Medical) were reported as former businesses recognized as discontinued operations, rather than part of the FY2025 continuing business-area mix.[28] [22]+7

Company history

Demant traces its origins to 1904, when Hans Demant began the business after selling the family’s first hearing aid on 8 June. In 1957, William Demant and his wife donated the family’s shares to the Oticon Foundation, establishing its long-term ownership role.[29][30]

From the mid-1990s, the company broadened beyond hearing aids through additions including Bernafon and MAICO and its stock-market listing; in 2000 it added Interacoustics and hearing-care clinic businesses.[31][32] Demant entered the headset business through a joint venture with Sennheiser in 2003, later operating that business as EPOS.[33] It acquired a controlling stake in hearing-care retailer Audika in 2015, and Oticon launched its Opn hearing-aid platform in 2016.[29][31] Søren Nielsen became President and CEO in 2017.[29]

In 2019, Demant introduced EPOS as its high-end audio-solutions business.[33] Oticon launched Intent in 2024, a hearing aid featuring user-intent sensors.[34][35] Demant agreed to sell Oticon Medical in 2025 and completed the divestment on 31 March 2026, ending its hearing-implants business area.[36][17] The acquisition of hearing-care retailer KIND, agreed in 2025, closed on 1 December that year.[37][38] [34]+10

Sources

• www.demant.com[1]
• DEMANT — Full financial report (2025 Y)
  16 citations

  [2][3][5][8][12][15][20][21][23][24][25][26][27][28][37][38]
• www.demant.com[4]
• DEMANT — Full financial report (2026 H 1)
  4 citations

  [6][7][16][18]
• www.demant.com[9]
• www.demant.com[10]
• www.demant.com[11]
• www.demant.com[13]
• www.demant.com[14]
• www.demant.com[17]
• www.demant.com[19]
• DEMANT — Presentation (2025 Y)[22]
• www.demant.com[29]
• www.demant.com[30]
• www.demant.com[31]
• www.demant.com[32]
• www.demant.com[33]
• DEMANT — Full financial report (2024 Y)[34][35]
• www.demant.com[36]